Opinion|Videos|March 14, 2025
CGM's Impact on Clinical Inertia
This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does CGM adoption impact clinical inertia and support earlier therapeutic interventions across different patient populations?
- What measurable improvements have been seen with CGMs in patient outcomes (eg, glycemic control, HbA1c levels, hypoglycemic events, quality of life)?
- Because each segment is considered a separate entity, each group of discussion questions should reset with No. 1 if using numbers.
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.
Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Youths with depression had about twice the odds of prescription drug misuse and 4 times the odds of use disorder, compared with peers without depression.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Experts Pitch National Risk Pool to Fund Gene Therapy Access
5